Published in Eur J Drug Metab Pharmacokinet on February 23, 2007
Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend (2012) 1.37
Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. Bioorg Med Chem (2012) 1.02
Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother (2002) 1.00
Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Br J Pharmacol (2014) 0.99
2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem (2007) 0.97
Potential anxiolytic agents. Part 4: novel orally-active N(5)-substituted pyrido[1,2-a]benzimidazoles with high GABA-A receptor affinity. Bioorg Med Chem Lett (2002) 0.95
Mephedrone interactions with cocaine: prior exposure to the 'bath salt' constituent enhances cocaine-induced locomotor activation in rats. Behav Pharmacol (2013) 0.90
Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Des (2003) 0.89
Development of a novel nonradiometric assay for nucleic acid binding to TDP-43 suitable for high-throughput screening using AlphaScreen technology. J Biomol Screen (2010) 0.87
2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. Bioorg Med Chem (2003) 0.85
Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines. Biochim Biophys Acta (2013) 0.84
Current nervous system related drug targets for the treatment of amyotrophic lateral sclerosis. Curr Pharm Des (2010) 0.84
Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the β-exosite. Bioorg Med Chem Lett (2012) 0.83
Characterization of a series of 4-aminoquinolines that stimulate caspase-7 mediated cleavage of TDP-43 and inhibit its function. Biochimie (2012) 0.82
Effects of atypical anxiolytic N-phenyl-2-[1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidine]acetamide (JNJ-5234801) on alcohol intake in alcohol-preferring P rats. Alcohol Clin Exp Res (2007) 0.81
Efficient conversion of substituted aryl thioureas to 2-aminobenzothiazoles using benzyltrimethylammonium tribromide. J Org Chem (2003) 0.81
Design, synthesis, and conformational analysis of eight-membered cyclic peptidomimetics prepared using ring closing metathesis. Bioorg Med Chem (2004) 0.81
Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ. Bioorg Med Chem (2012) 0.81
Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. J Med Chem (2014) 0.80
Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies. J Med Chem (2009) 0.80
Assessing activity onset time and efficacy for clinically effective antidepressant and antimanic drugs in animal models based on dominant-submissive relationships. Neurosci Biobehav Rev (2007) 0.78
The in vitro metabolism of thalicarpine, an aporphine-benzyltetrahydroisoquinoline alkaloid, in the rat. API-MS/MS identification of thalicarpine and metabolites. J Pharm Biomed Anal (2002) 0.78
Small molecule anticonvulsant agents with potent in vitro neuroprotection. J Mol Neurosci (2012) 0.77
Preparation of 3-spirocyclic indolin-2-ones as ligands for the ORL-1 receptor. Bioorg Med Chem Lett (2005) 0.77
3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett (2006) 0.77
Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112). J Med Chem (2013) 0.76
Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: an inhibitor of beta-amyloid(1-42) aggregation. Bioorg Med Chem (2002) 0.76
5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther (2002) 0.76
A high-throughput monoamine oxidase inhibition assay using liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom (2004) 0.76
Linear interaction energy models for beta-secretase (BACE) inhibitors: Role of van der Waals, electrostatic, and continuum-solvation terms. J Mol Graph Model (2005) 0.76
Synthesis and biological evaluation of type VI beta-turn templated RGD peptidomimetics. Bioorg Med Chem Lett (2006) 0.75
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads. Bioorg Med Chem Lett (2010) 0.75
Facile Synthesis of Mutagen X (MX): 3-Chloro-4-(dichloromethyl)-5-hydroxy-5H-furan-2-one. Tetrahedron Lett (2012) 0.75
Small-molecule anticonvulsant agents with potent in vitro neuroprotection and favorable drug-like properties. J Mol Neurosci (2013) 0.75
In-vitro metabolism of isotetrandrine, a bisbenzylisoquinoline alkaloid, in rat hepatic S9 fraction by high-performance liquid chromatography-atmospheric pressure ionization mass spectrometry. J Pharm Pharmacol (2004) 0.75
Editorial. Curr Top Med Chem (2009) 0.75
In vitro metabolism of the new anxiolytic agent, RWJ-52763 in human hepatic S9 fraction-API-MS/MS identification of metabolites. J Pharm Biomed Anal (2003) 0.75
Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect. Bioorg Med Chem Lett (2004) 0.75
Hepatic biotransformation of the new calcium-mimetic agent, RWJ-68025, in the rat and in man--API-MS/MS identification of metabolites. J Pharm Pharmacol (2003) 0.75
In-vitro metabolism of the new anxiolytic agent, RWJ-50172, in rat hepatic S9 fraction and microbial transformation in fungi, Cunninghamella sp. J Pharm Pharmacol (2003) 0.75
N-alkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, micro and delta opioid agonists: a micro address. Bioorg Med Chem Lett (2004) 0.75
Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites. Eur J Drug Metab Pharmacokinet (2007) 0.75
8-(Heteroaryl)phenalkyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-ones as opioid receptor modulators. Med Chem (2005) 0.75
Preface. Curr Top Med Chem (2012) 0.75
Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi]. Drug Discov Today (2008) 0.75
Many, diverse topics have been covered in recent years in CTMC. Preface. Curr Top Med Chem (2015) 0.75
The synthesis and evaluation of 10- and 12-membered ring benzofused enediyne amino acids. Bioorg Med Chem (2005) 0.75
Diarylacetylene piperidinyl amides as novel anxiolytics. Bioorg Med Chem Lett (2006) 0.75
Noncovalent self-assembly of bicyclo[4.2.2]diketopiperazines: influence of saturation in the bridging carbacyclic ring. Org Lett (2004) 0.75
Distribution and metabolism of the antipsychotic agent mazapertine succinate in rats. J Pharm Biomed Anal (2005) 0.75